Stock APRE APREA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Real-time Estimate Cboe BZX
Other stock markets
 14:56:49 2024-06-26 EDT 		5-day change 1st Jan Change
4.115 USD -0.84% Intraday chart for Aprea Therapeutics, Inc. +2.83% -10.96%
06-24 Transcript : Aprea Therapeutics, Inc. - Special Call
06-17 Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Aprea Therapeutics, Inc. - Special Call
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
AQ
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
AQ
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
CI
Aprea Therapeutics Announces that Safety Review Committee Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical trial
AQ
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
AQ
Aprea Therapeutics, Inc. Announces Safety Review Committee Endorses Dosing of Patients with ATRN-119 at 800 Mg Once Daily in Ongoing ABOYA-119 Clinical Trial
CI
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
AQ
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
AQ
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
AQ
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza as Chief Medical Officer
CI
Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024
CI
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
AQ
Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating
MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading
MT
Aprea Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
AQ
Aprea Therapeutics Receives FDA Approval of the IND Application for the Drug Candidate Apr-1051
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APRE Stock
  4. News Aprea Therapeutics, Inc.